Galapagos NV Stock News

Shares of Galapagos NV (NASDAQ:GLPG) have earned a consensus rating of “Hold” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating on the company. The average […]

Related Stocks: RCUS , GRTS , RNA , NRIX , DSGN , ODT , GLPG , PTGX , TNGX , ERAS , IMVT , BLUE , TBIO , KYMR , ARVN , BCEL , KDNY , ZNTL ,

Mechelen, Belgium; 15 November 2021; 16.45 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca (filgotinib 200m

Mechelen, Belgium; 15 November 2021; 16.45 CET; Galapagos NV (Euronext Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca ® (filgotinib 200mg tablets) for the treatment of adult patients with moderately to severely

Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call Transcript

Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).  The analyses showed clinical

Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in patients with Crohn's Disease (CD). The D

When any team underperforms, it's usually the manager or coach who gets the axe. The same often holds true in the corporate world.

After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership. He will stay in his role until

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call Transcript

The company's new salt-inducable kinase inhibitor program is getting off to a rocky start.

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

Galapagos NV (NASDAQ: GLPG) reported topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients. At Week 4, four out of 10 patients in the high dose

Galapagos NV (NASDAQ: GLPG) reports topline results from three studies evaluating GLPG3970, a SIK inhibitor, in psoriasis, ulcerative colitis (UC), and rheumatoid arthritis (RA).  26-patient CALOSO

Mechelen, Belgium; 14 July 2021; 2 2 . 01 CET ; regulated information – Galapagos NV (Euronext & Nasda q : GLPG) reports topline results with GLPG3970 in three pati e nt studies . GLPG3970 , the fir